TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05141474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXTGEN-TIL
Description: NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Lymphodepletion (NMA-LD) Regimen
Description: Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped.
Study: NCT06581081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl_B19 autologous CAR-T (S1904) treatment
Description: Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Senl_B19 autologous CAR-T (S1904) treatment
Description: Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment.
Study: NCT05894239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phesgo
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Taxane-based Chemotherapy
Description: During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
Study: NCT04104477

Intervention type: OTHER
Intervention: Range of Motion Tasks
Description: Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.

Intervention type: OTHER
Intervention: Strength Tasks
Description: Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
Study: NCT05894239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Endocrine Therapy of Investigator's Choice
Description: Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optional Endocrine Therapy of Investigator's Choice
Description: Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Study: NCT04104477

Intervention type: OTHER
Intervention: Strength Tasks
Description: Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
Study: NCT04722679

Intervention type: DRUG
Intervention: Non-VKA Oral Anticoagulants (NOAC)
Description: Follow clinical practice.

Intervention type: DRUG
Intervention: Non-VKA Oral Anticoagulants (NOAC)
Description: Follow clinical practice.
Study: NCT06028256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine Hydrochloride
Description: Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform.~Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
Study: NCT05889130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Exercise
Description: The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control.
Study: NCT05575843

Intervention type: OTHER
Group type: OTHER
Intervention: Neurostatus-SMARTCARE
Description: The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.

Intervention type: OTHER
Group type: OTHER
Intervention: Neurostatus-SMARTCARE
Description: The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Neurostatus-EDSS
Description: The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
Study: NCT04812015

Intervention type: DEVICE
Group type: OTHER
Intervention: transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes
Description: Sham 60 minutes and taVNS active stimulation for 15 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: taVNS 30 minutes
Description: Sham 45 minutes and taVNS active stimulation for 30 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: taVNS 45 minutes
Description: Sham 30 minutes and taVNS active stimulation for 45 minutes
Study: NCT05579561

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
Study: NCT06255990

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care
Study: NCT06403384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Local vibration was applied
Study: NCT04812015

Intervention type: DEVICE
Group type: OTHER
Intervention: taVNS 60 minutes
Description: Sham 15 minutes and taVNS active stimulation for 60 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: taVNS 75 minutes
Description: Sham 0 minutes and taVNS active stimulation for 75 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: taVNS 0 minutes
Description: Sham taVNS 75 minutes
Study: NCT04885231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Pain Management Education and Counseling
Description: All patients will receive both verbal postoperative pain management education and counseling as well as a written handout. Multi-modality non-opioid methods of pain control will be thoroughly discussed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Pain Management Education and Counseling
Description: All patients will receive both verbal postoperative pain management education and counseling as well as a written handout. Multi-modality non-opioid methods of pain control will be thoroughly discussed.
Study: NCT04653454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: CGM data will be downloaded prior to discharge and it will be compared with hospital glucometer readings taken at the same time.
Study: NCT05441579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economics (BE) recruitment strategies
Description: Behavioral economics (BE), a method of economic analysis that applies psychological insights into human behavior to explain economic decision-making, has broad applicability and its techniques offer a novel way that may be applied to try to help enhance study recruitment and enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economics (BE) recruitment strategies
Description: Behavioral economics (BE), a method of economic analysis that applies psychological insights into human behavior to explain economic decision-making, has broad applicability and its techniques offer a novel way that may be applied to try to help enhance study recruitment and enrollment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback-based virtual reality (VR-BF)
Description: Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback-based virtual reality (VR-BF)
Description: Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
Study: NCT05214144

Intervention type: OTHER
Intervention: PRO Instruments assessment questionnaire
Description: Patient Reported Outcome (PRO) questionnaire consisting of:~* PRO-CTCAE (approximately 11 questions plus free text)~* Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~* PRO ECOG question (1 question)~* EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~* Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~* The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)

Intervention type: OTHER
Intervention: Baseline Survey Clinician- reported (ClinRO) ECOG
Description: Baseline Survey completed prior to initiation of chemotherapy

Intervention type: DEVICE
Intervention: Fitbit
Description: wearable device

Intervention type: OTHER
Intervention: Hugo Health (Hugo)
Description: an electronic platform that aggregates real world EHR data with patient's wearable and PRO data

Intervention type: OTHER
Intervention: 6 Minute Walk Test (6MWT)
Description: A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
Study: NCT04534985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
Study: NCT05575843

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Neurostatus-EDSS
Description: The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
Study: NCT05228652

Intervention type: OTHER
Intervention: Questionnaire
Description: Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.

Intervention type: OTHER
Intervention: Questionnaire
Description: Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
Study: NCT06191354

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0201 Injection
Description: SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
Study: NCT04448327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tVNS
Description: non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tVNS
Description: Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
Study: NCT05004480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Electronic treadmill, Hammer T-2000 Treadmill, 2,5 HP - 140 Kilograms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Electronic treadmill, Hammer T-2000 Treadmill, 2,5 HP - 140 Kilograms
Study: NCT04895787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait + aerobic exercise
Description: Following skill-based gait training, the participants in the AEX group will engage in 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle. The participants will first perform a brief warm-up, followed by 20 minutes of moderate to high intensity aerobic exercise pedaling at 60-80 rpm with a target heart rate range between 60-70% of heart rate reserve (HRR). Given the potential of having autonomic dysfunction in this population, it has been suggested that a RPE scale between 14-17 is appropriate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait + resistance exercises
Description: Following skill-based gait training, the participants in the REX group will engage in resistance training, which will target major muscle groups important for daily activities. The resistance training will be provided with free weights or therabands at an intensity of 8-12 repetition maximum (RM). Each muscle group should be trained with 8-12 repetitions ranging from 1 to 3 sets with resting intervals provided between each set. The target RPE scale will be set between 14-17, and the training load will be progressively increased as the participants improved.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait + conventional physical therapy
Description: Following skill-based gait training, the participants in the CPT group will receive conventional physical therapy, which may include stretching exercise, balance training, or practice over-ground walking based on the participant's need.
Study: NCT05002140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRD-0394
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRD-0394
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRD-0394
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRD-0394
Description: Single ascending dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: 4 Gy × 5 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: 4 Gy × 5 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: 4 Gy × 5 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: 4 Gy × 5 daily fractions
Study: NCT05441579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manage My Pain
Description: Commercially available and free app to track, analyze and monitor pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manage My Pain
Description: Commercially available and free app to track, analyze and monitor pain.
Study: NCT05137626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 + digoxin
Description: * Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 + digoxin
Description: * Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later).
Study: NCT06347159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-7500
Description: Liquid suspension formulation of EDG-7500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-7500
Description: Solid oral formulation of EDG-7500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-7500
Description: Solid oral formulation of EDG-7500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-7500
Description: Solid oral formulation of EDG-7500
Study: NCT06481176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-Week RLS Exercise Program
Description: Participants will complete 12 weeks of an evidence-based exercise program that has been used for people with RLS, designed for people with RLS, and was informed by exercise guidelines outlined by the American College of Sports Medicine (ACSM) and the American Heart Association, and Center for Disease Control.~The program includes three sessions per week for 12 weeks including:~* cardiovascular exercise (e.g., walking/jogging, bicycling) for 30 minutes/day on at least 3 days/week at a moderate-to-vigorous intensity~* strength training on 2 non-consecutive days/week targeting major muscle groups for approximately 30 minutes~* Stretching all major muscle groups on three or more days per week
Study: NCT04711135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium [177Lu] oxodotreotide/dotatate
Description: Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Study: NCT05304936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCW9218
Description: Bifunctional TGF-β antagonist/IL-15 protein complex
Study: NCT04945642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo HDR-BT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT04864106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Examination
Description: Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
Study: NCT06632769

Intervention type: DEVICE
Intervention: No intervention
Description: No intervention
Study: NCT04999774

Intervention type: DIAGNOSTIC_TEST
Intervention: Different diagnostic tests
Description: Each SAC will be tested with all tests
Study: NCT04699253

Intervention type: DEVICE
Intervention: SanaCoach Heart failure
Description: Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
Study: NCT04802005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training
Description: The aerobic interval training group
Study: NCT05309577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Self-Monitoring + Motivational Interviewing
Description: Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
Study: NCT05656274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS1-1-01
Description: Oral tables

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tables
Study: NCT05454891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended bolus of insulin then standard bolus of insulin
Description: For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard bolus of insulin then extended bolus of insulin
Description: For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
Study: NCT05198505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2868 Injection
Description: TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
Study: NCT05905796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Health Assessment
Description: Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
Study: NCT05815329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.